Page 290 - ebook HCC

PROGRAMME
GENEV
EASL HCC SUMMITHCC SUMMIT
288
288 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEVA, SWITZERLANDA, SWITZERLAND EASL 289
289
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C59
HIGH LEVELS OF CIRCULATING ENDOTHELIAL
CELLS AND RISK OF PROGRESSION IN
PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC HEPATOCELLULAR CARCINOMA
RECEIVING SORAFENIB

Petros Giovanis , Valter Vincenzi , Graziano Pianezze , Carla Manuppelli , Median baseline CECs and HPCs levels were 67 cells/ml (range 10-141) and 1300 cells/
1
2
3
2
Manuele Toniolo , Dagmar Dannhauser , Laura Ciasullo , Massimo Boaretto , ml (range 342-2546), respectively. After 4 weeks of treatment we observed a 169.8%
2
2
2
3
Mauro Giusto , Patrizia Pontisso 4 increase in CECs levels, and a 71.3% decrease in HPCs levels. A continuous increase
1
1 Medical Oncology, Internal Medicine, Research Laboratory, Azienda Ulss 1, Belluno, on CECs levels was observed in all pts who interrupted the treatment for PD or major
3
2
4
Italy, Belluno, Department of Medicine, University of Padua, Padua, Italy toxicity. An opposite kinetic effect was observed in all 3 pts still on treatment, where
CECs returned to baseline levels within 12 weeks of treatment.
Corresponding author’s e-mail: pgiova@racine.ra.it
Conclusion: Treatment with sorafenib significantly changed CECs levels in HCC pts.
Continuous increase of CEC counts during sorafenib treatment was observed with
Introduction: Circulating endothelial cells (CEC) seems to reflect the activity of rapid progression, while a decrease in the CECs numbers was observed with stable
antiangiogenic agents on tumor neo-angiogenesis. disease and delayed tumor progression. The modulation of this cell population might
be critical for achieving treatment response or induce resistance to sorafenib or other
Aims: In this hypothesis-generated study we investigated the behaviour of CEC and antiangiogenic agents. Further investigation into the possible role of CECs as potential
hematopoietic progenitor cells (HPC) in patients (pts) with hepatocellular carcinoma biomarker or as a target of anti-angiogenic therapy are warranted.
(HCC) receiving sorafenib, and whether CECs levels were associated with time to
progression (TTP).
Methodology: CECs (CD45 neg /CD34 bright /CD31 /CD146 /VEGFR2 ) and HPCs
pos
pos
pos
(CD45 /CD34 bright ) of advanced HCC pts receiving sorafenib 400 mg twice daily were
dim
CLINICAL POSTER ABSTRACTS was performed with CT (or MRI) according to RECIST criteria. CLINICAL POSTER ABSTRACTS
counted in fresh blood samples using four-color flow cytometry at baseline and every 4
weeks until disease progression or unacceptable toxicity. Assessment of tumor response
Results: Twenty-four HCC pts, 23 men and 1 female, median age 70 years (range 52-
83), Child-Pugh class A were enrolled in the study. The etiology was alcoholic cirrhosis
in 20 pts, chronic hepatitis C virus infection in 4 pts. Stage of disease was BCLC C in
13 pts, stage B not amendable any more to loco-regional treatment in 11 pts. All pts
previously received loco-regional therapies. Three pts are still on treatment at 4, 17, 19
months, presenting stable disease. Twenty one pts interrupted treatment, of which 17
for progressive disease (PD) with a TTP of 3.2 months (range 1-6), and 4 for adverse
events: severe asthenia, anorexia and weight loss, after 22 days (range 15-35).